Filter Results
Clinical Studies
Results filtered:Study status:
Open
Closed for Enrollment
Open
-
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy
Rochester, Minn.
The purpose of this study is to evaluate the effectiveness of TAK-341 versus placebo, as measured by the change from baseline to Week 52 on l Unified Multiple System Atrophy Rating Scale (UMSARS) Part I, minus the sexual function item, with collapse of the normal and mild ratings on each item.
-
Double-Blind, Placebo-Controlled Study of Pyridostigmine in Postural Tachycardia Syndrome
Rochester, Minn.
This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.
Closed for Enrollment
-
A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy
Rochester, Minn.
The purpose of the study is to see if administering intravenous immune globulin (IVIG) (putting immune globulin directly into your blood) helps to improve the symptoms of orthostatic hypotension (sudden fall in blood pressure when a person stands up) and quality of life in men and women who have autoimmune autonomic ganglionopathy (AAG).
-
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR)
Rochester, Minn.
The purpose of this study is to compare the effectiveness of BHV-3241 versus placebo in subjects with Multiple System Atrophy.
-
Double-Blind, Placebo-Controlled Study of Rifampicin in Multiple System Atrophy (MSA)
Rochester, Minn.,
Jacksonville, Fla.
The purpose of this study is to determine the effectiveness of Rifampicin in slowing or reversing the progression of multiple system atrophy.
-
Treatment Trial of Droxidopa and Pyridostigmine to Improve Orthostatic Hypotension Without Aggravating Supine Hypertension
Rochester, Minn.
The hypothesis is that pyridostigmine will improve the safety factor of ganglionic neural transmission, while Droxidopa will replete the postganglionic neuron of norepinephrine (NE). This combination should result in enhanced orthostatic release of NE. The investigators have already demonstrated that pyridostigmine does not raise supine blood pressure.
.